Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo TID Clear all
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

NCT00443079
View directory record Official record
Conditions
Fatty Liver
Interventions
IdB 1016 (Siliphos), Matched placebo
Drug
Lead sponsor
Heather Patton
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

LMN-101 in a Campylobacter Human Challenge Model

NCT04182490
View directory record Official record
Conditions
Campylobacter Infections
Interventions
LMN-101, Placebo
Biological · Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Pentoxifylline on PAI-1 in an Obese Population

NCT00770328
View directory record Official record
Conditions
Obesity
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

NCT00571922
View directory record Official record
Conditions
Methamphetamine Dependence, Treatment Seeking
Interventions
Acamprosate, placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 27, 2026, 6:14 AM EDT
Withdrawn Phase 2 Interventional

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NCT04713202
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
Interventions
Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo
Drug · Other
Lead sponsor
Chandrikha Chandrasekhara
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gabapentin in Patients at Clinical Risk for Psychosis

NCT02557945
View directory record Official record
Conditions
Clinical High Risk for Psychosis
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

NCT01364467
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Placebo, Guaifenesin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

NCT07456800
View directory record Official record
Conditions
Pharmacokinetic Analysis
Interventions
Deupirfenidone, Pirfenidone (PFD), Placebo
Drug
Lead sponsor
PureTech
Industry
Eligibility
60 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Lake Mary, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Arginine Therapy for Sickle Cell Disease Pain

NCT02536170
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions
L-arginine, L-arginine Loading Dose, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
3 Years to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Not applicable Interventional

The Effect of Lysulin on Glycemic Control and Advanced Glycation

NCT04234581
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lysulin
Dietary Supplement
Lead sponsor
Juraj Koska
Federal
Eligibility
21 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

NCT01137955
View directory record Official record
Conditions
Celiac Disease
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

NCT01426009
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 27, 2026, 6:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Homeopathic Drug Provings

NCT00809263
View directory record Official record
Conditions
Healthy
Interventions
homeopathic remedy
Drug
Lead sponsor
Integrative Medicine Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

NCT05323734
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

NCT04378075
View directory record Official record
Conditions
Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions
Vatiquinone, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 20 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 58 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Phase 2Phase 3 Interventional

Cranberry Juice for Treatment of Urinary Tract Infections

NCT00093054
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cranberry juice, Placebo cranberry juice
Drug · Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

NCT05081882
View directory record Official record
Conditions
Smoking
Interventions
Kava, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF

NCT03864328
View directory record Official record
Conditions
Persistent Cough in IPF, Chronic Cough, IPF
Interventions
RVT-1601, Placebo
Drug
Lead sponsor
Respivant Sciences GmbH
Industry
Eligibility
40 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 27, 2026, 6:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model

NCT01965600
View directory record Official record
Conditions
Healthy
Interventions
PF-06282999, Placebo, LPS
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 27, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Study Investigating the Effects of a Novel Weight Management Program

NCT01875354
View directory record Official record
Conditions
Overweight
Interventions
Dietary Supplements and TR90 Eating Plan, Placebo and Low Fat Eating Plan
Dietary Supplement
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 65 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 27, 2026, 6:14 AM EDT